Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free PHXM Stock Alerts

PHAXIAM Therapeutics (PHXM) Competitors

PHAXIAM Therapeutics logo
$3.10 0.00 (0.00%)
As of 05/22/2026
Compare

PHXM vs. TLPH, ATOS, MIRA, TELO, and ATHA

Should you buy PHAXIAM Therapeutics stock or one of its competitors? MarketBeat compares PHAXIAM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PHAXIAM Therapeutics include Talphera (TLPH), Atossa Genetics (ATOS), MIRA Pharmaceuticals (MIRA), Telomir Pharmaceuticals (TELO), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry.

How does PHAXIAM Therapeutics compare to Talphera?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PHAXIAM Therapeutics has higher earnings, but lower revenue than Talphera.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A
Talphera$30K1,410.12-$14.29M-$0.31N/A

In the previous week, Talphera had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Talphera and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Talphera's score of -0.19 indicating that PHAXIAM Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Talphera Neutral

PHAXIAM Therapeutics' return on equity of 0.00% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
Talphera N/A -92.98%-53.22%

Talphera has a consensus price target of $3.00, indicating a potential upside of 268.05%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Talphera
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, Talphera has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Summary

Talphera beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

PHAXIAM Therapeutics' return on equity of 0.00% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -84.91% -72.36%
PHAXIAM Therapeutics N/A N/A N/A

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

In the previous week, Atossa Genetics had 3 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 3 mentions for Atossa Genetics and 0 mentions for PHAXIAM Therapeutics. PHAXIAM Therapeutics' average media sentiment score of 0.00 beat Atossa Genetics' score of -0.74 indicating that PHAXIAM Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Atossa Genetics Negative
PHAXIAM Therapeutics Neutral

Atossa Genetics presently has a consensus price target of $36.33, suggesting a potential upside of 632.53%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Genetics is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.40
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Atossa Genetics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Summary

Atossa Genetics beats PHAXIAM Therapeutics on 7 of the 12 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

PHAXIAM Therapeutics (NASDAQ:PHXM) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
MIRA Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

In the previous week, PHAXIAM Therapeutics' average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
PHAXIAM Therapeutics Neutral
MIRA Pharmaceuticals Neutral

PHAXIAM Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
MIRA Pharmaceuticals N/A -140.82%-135.01%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A
MIRA PharmaceuticalsN/AN/A-$10.44M-$1.30N/A

Summary

PHAXIAM Therapeutics and MIRA Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Telomir Pharmaceuticals?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.29N/A

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Telomir Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. Telomir Pharmaceuticals' average media sentiment score of 0.71 beat PHAXIAM Therapeutics' score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
PHAXIAM Therapeutics Neutral
Telomir Pharmaceuticals Positive

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

PHAXIAM Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
PHAXIAM TherapeuticsN/A N/A N/A
Telomir Pharmaceuticals N/A -201.23%-172.71%

Summary

PHAXIAM Therapeutics beats Telomir Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

In the previous week, Athira Pharma had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Athira Pharma and 0 mentions for PHAXIAM Therapeutics. Athira Pharma's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company Overall Sentiment
Athira Pharma Neutral
PHAXIAM Therapeutics Neutral

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athira PharmaN/AN/A-$96.94M-$9.68N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

PHAXIAM Therapeutics' return on equity of 0.00% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Athira PharmaN/A -107.06% -89.89%
PHAXIAM Therapeutics N/A N/A N/A

Athira Pharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Athira Pharma currently has a consensus price target of $4.00, suggesting a potential downside of 61.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than PHAXIAM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PHAXIAM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Athira Pharma beats PHAXIAM Therapeutics on 6 of the 9 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHXM vs. The Competition

Export
MetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$10.58M$470.48M$6.46B$12.34B
Dividend YieldN/A3.87%2.76%5.28%
P/E RatioN/A3.8621.2225.66
Price / SalesN/A7,482.36562.2886.31
Price / CashN/A13.1343.4956.67
Price / Book0.3984.1310.317.14
Net Income-$240K-$96.07M$3.57B$335.98M
7 Day PerformanceN/A0.16%6.43%4.15%
1 Month PerformanceN/A0.72%3.57%2.54%
1 Year PerformanceN/A63.70%34.07%35.06%

PHAXIAM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat		N/AN/A$10.58MN/AN/A49
TLPH
Talphera
3.2377 of 5 stars		$0.83
+4.3%		$3.00
+260.7%		+61.1%$41.38M$30KN/A19
ATOS
Atossa Genetics
2.528 of 5 stars		$4.74
-0.8%		$36.33
+666.5%		-60.2%$41.16MN/AN/A8
MIRA
MIRA Pharmaceuticals
0.4574 of 5 stars		$0.95
-2.7%		N/A-18.7%$41.01MN/AN/A2
TELO
Telomir Pharmaceuticals
1.442 of 5 stars		$1.22
+2.5%		N/A-38.6%$40.91MN/AN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel